Skip to main content

Table 1 Baseline demographic characteristics of participants randomized to rosuvastatin, aspirin, or placeboa

From: Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin

Variable

Overall sample

(N = 130)

Rosuvastatin (n = 48)

Aspirin

(n = 40)

Placebo

(n = 42)

 

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

Age (years)

20·2 (2·6)

20·0 (2·7)

20·7 (2·7)

20·0 (2·4)

BMI

25·8 (7·6)

24·3 (6·9)

25·3 (8·1)

27·6 (7·4)

 

N (%)

N (%)

N (%)

N (%)

Gender

 Female

77 (59·2)

28 (58·3)

25 (62·5)

24 (57.1)

Age (younger than 18)

29 (22·3)

13 (27·1)

8 (20·0)

8 (19·0)

English first language

119 (91·5)

44 (91.7)

38 (95·0)

37 (88·1)

Occupationb

 Student

55 (42·3)

22 (45·8)

16 (40·0)

17 (40·5)

 Full-time employment

8 (6·2)

3 (6·3)

3 (7·5)

2 (4·8)

 Part time/ Casual

36 (27·7)

14 (29·2)

11 (27·5)

11 (26·2)

 unemployed

28 (21·5)

8 (16·7)

11 (27·5)

9 (21·4)

Living statusc

 Parents

82 (63·1)

25 (52·1)

26 (65·0)

31 (73·8)

 Friends

16 (12·3)

8 (16·7)

4 (10·0)

4 (9·5)

 Spouse/ De facto

12 (9·2)

5 (10·4)

6 (15·0)

1 (2·4)

 Alone

5 (3·8)

3 (6·3)

2 (5·0)

0 (0·0)

Psychosocial therapy during lifetime (yes)

111 (85·4)

40 (83·3)

34 (85·0)

37 (88·1)

Ongoing psychological therapy during study (yes)

90 (69.2)

31 (64.6)

31 (77.5)

28 (66.7)

Antidepressant use (yes)

109 (83·0)

37 (77·1)

35 (87·5)

37 (88·1)

Ongoing antidepressant use during study (yes)

39 (30·0)

13 (27·1)

14 (35·0)

12 (28·6)

CSSRS – past month

 Suicidal ideation

124 (95·4)

46 (95·8)

38 (95·0)

40 (95.2)

 Suicidal behaviors

10 (7·7)

3 (6·3)

5 (12·5)

2 (4·8)

 Suicidal acts

6 (4·6)

2 (4·2)

3 (7·5)

1 (2·4)

 Non-suicidal self-injury

23 (17·7)

10 (20·8)

6 (15·0)

7 (16·7)

Number of major

 Depressive episodes

3 (1, 6)

3 (3, 6)

2 (1, 6)

4 (2, 8)

 Duration, weeks

24 (12, 52)

20 (20, 44)

32 (16, 80)

26 (12, 39)

 Anxiety disorder

81 (62·3)

31 (64·6)

28 (70·0)

22 (52·4)

 Substance use disorder

17 (13·1)

7 (14·6)

4 (10·0)

6 (14·3)

Number of concomitant medications (median, IQR)

3 (2, 5)

3 (2, 4·25)

3 (2, 5)

4.5 (2, 6)

  1. aThere were no significant differences between groups on any variable
  2. bOther occupations include caregiver (n = 1), and volunteer work (n = 1)
  3. cOther living status include other relatives (n = 2) and other arrangements (n = 10)